Senior Director, Oncology Clinical Educators

Senior Director, Oncology Clinical Educators Remote-Field (US) About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland. Overview of Role: The Senior Director, Oncology Clinical Educators will establish and lead Summit Therapeutics’ field based Clinical Educator function, developing the strategy, infrastructure, and capabilities to support the launch and commercialization of the Company’s oncology portfolio, beginning with its NSCLC bispecific antibody. This leader will oversee the delivery of compliant, on-label education to healthcare professionals to support clinical readiness and appropriate treatment implementation. This leader will lead the national education strategy, establish territory coverage and priorities, and partner cross-functionally while maintaining appropriate compliance oversight. The role is not a sales or marketing role, its educational objectives, performance measures, and incentives will remain independent of sales and marketing performance. Role and Responsibilities: Establish and lead the Oncology Clinical Educator function, defining the vision, strategy, operating model, and annual priorities to support launch readiness and evolving business needs. Develop and execute a national clinical education strategy, including territory design, resource allocation, account prioritization, and educational engagement plans across academic and community oncology settings. Recruit, develop, coach, and retain Clinical Educators, and build a high-performing, clinically credible team, fostering clinical excellence, accountability, collaboration, and continuous professional development. Provide strategic leadership and oversight of field execution, ensuring consistent, high-quality educational engagement and responsiveness to evolving healthcare professional needs. Collaborate with Medical Affairs, Legal, and Compliance to establish and maintain a compliant educational framework, ensuring activities are on-label, use approved materials, address legitimate educational needs, and remain appropriately independent of promotional objectives and incentives. Maintain clear separation between clinical education and promotional activities, ensuring the team's educational objectives, performance measures, and incentives remain independent of sales and marketing performance, in partnership with Legal, Compliance, and Medical Affairs. Partner strategically and cross functionally with Field Sales, Marketing, Market Access, Training, and Medical Affairs and other key stakeholders to align educational priorities with organizational needs while maintaining appropriate role boundaries. Lead the identification and assessment of educational gaps, clinical practice needs, treatment workflows, and patient management considerations to inform educational strategies and resources. Establish performance measures and reporting processes to evaluate educational effectiveness, field engagement, and healthcare professional readiness, providing meaningful insights and recommendations to senior leadership independent of sales performance. Oversee the Clinical Educator budget, headcount planning, resource allocation, and vendor relationships to ensure effective and responsible management of resources. Establish and maintain appropriate relationships with professional nursing organizations, oncology association, and other relevant external stakeholders to identify educational needs and opportunities for collaboration Build and maintain the infrastructure, processes, systems, and governance necessary to support a scalable and effective Clinical Education function. Ensure the team maintains current knowledge of oncology disease states, approved product information, clinical developments, and the evolving treatment landscape through ongoing training and professional development. Serve as a strategic advisor to senior leadership, communicating field educational insights, emerging needs, operational challenges, and opportunities to strengthen the clinical education capabilities. Model and follow Summit Therapeutics’ core values and demonstrate the highest standards of integrity, professionalism, and ethical conduct. All other duties as assigned Experience, Education and Specialized Knowledge and Skills: Education: BSN required. Graduate-level nursing degree (MSN, NP, DNP, APRN, or CNS) preferred. Oncology certification preferred. Minimum of 10+ years of clinical oncology experience required, with solid tumor and NSCLC experience preferred. Minimum of 10+ years total relevant experience, including 5 years leading field-based teams. Clinical Educator leadership in the pharmaceutical or biotechnology industry and a prior oncology launch preferred. Specialized Knowledge and Skills: Working knowledge of pharmaceutical regulatory and compliance requirements. Strong presentation, communication, and cross-functional collaboration skills. Able to lead in technically complex and ambiguous environments Travel: Approximately 30% of travel expected This is the pay for this position Pay Transparency

$197,000 - $246,500 USD

Actual compensation packages are based on several factors that are unique to each candidate, including but not limited to skill set, depth of experience, certifications, and specific work location. This may be different in other locations due to differences in the cost of labor. The total compensation package for this position may also include bonus, stock, benefits and/or other applicable variable compensation. Summit does not accept referrals from employment businesses and/or employment agencies in respect of the vacancies posted on this site. All employment businesses/agencies are required to contact Summit’s Talent Acquisition team at View email address on click.appcast.io to obtain prior written authorization before referring any candidates to Summit. Summit Therapeutics Inc.is an Equal Opportunity Employer and takes pride in creating and maintaining diverse environment. We do not discriminate in recruitment, hiring, training or promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status. Voluntary Self-Identification For government reporting purposes, we ask candidates to respond to the below self-identification survey.Completion of the form is entirely voluntary. Whatever your decision, it will not be considered in the hiringprocess or thereafter. Any information that you do provide will be recorded and maintained in aconfidential file. As set forth in Summit Therapeutics’s Equal Employment Opportunity policy,we do not discriminate on the basis of any protected group status under any applicable law. If you believe you belong to any of the categories of protected veterans listed below, please indicate by making the appropriate selection.As a government contractor subject to the Vietnam Era Veterans Readjustment Assistance Act (VEVRAA), we request this information in order to measurethe effectiveness of the outreach and positive recruitment efforts we undertake pursuant to VEVRAA. Classification of protected categoriesis as follows: A "disabled veteran" is one of the following: a veteran of the U.S. military, ground, naval or air service who is entitled to compensation (or who but for the receipt of military retired pay would be entitled to compensation) under laws administered by the Secretary of Veterans Affairs; or a person who was discharged or released from active duty because of a service-connected disability. A "recently separated veteran" means any veteran during the three-year period beginning on the date of such veteran's discharge or release from active duty in the U.S. military, ground, naval, or air service. An "active duty wartime or campaign badge veteran" means a veteran who served on active duty in the U.S. military, ground, naval or air service during a war, or in a campaign or expedition for which a campaign badge has been authorized under the laws administered by the Department of Defense. An "Armed forces service medal veteran" means a veteran who, while serving on active duty in the U.S. military, ground, naval or air service, participated in a United States military operation for which an Armed Forces service medal was awarded pursuant to Executive Order 12985. #J-18808-Ljbffr Summit-Therapeutics